Core Viewpoint - The stock price of药捷安康-B (02617.HK) experienced significant volatility, dropping 45% after previously surging 63% to a peak of 679.5 HKD per share [1][3]. Company Overview -药捷安康 is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [3]. - The company has no commercialized products and reported zero revenue with a loss of 123 million HKD in the first half of the year [3]. Stock Performance - The stock price increased dramatically, with a cumulative rise of over 30 times since its IPO price of 13.15 HKD, reaching a market capitalization exceeding 120 billion HKD [3]. - The stock was recently included in the Hong Kong Stock Connect program, allowing southbound funds to invest in it [3]. Clinical Developments - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval from the National Medical Products Administration of China for a Phase II trial in treating HR+/HER2- metastatic breast cancer [3][4]. - Early clinical results indicated promising effects of Tinengotinib as a monotherapy in patients with HR+/HER2- breast cancer who have undergone multiple treatments [4]. Competitive Landscape - There are currently no other products in development with the same mechanism as Tinengotinib, although there are various competitors in related cancer treatment areas [7]. - The market for small molecule drugs is competitive, with larger biologics generally having greater potential [7]. Shareholding Structure - The founder, Wu Yongqian, holds a 32.98% stake in the company, contributing to a limited market float with only 15.281 million shares available for trading out of a total of 397 million shares [7]. - The stock exhibited a trading volatility of 131.09% with a low turnover rate of 4.74% as of September 12 [7]. Company History -药捷安康 has faced challenges in its journey to listing, having attempted to go public on three occasions in 2021, 2022, and 2024 [8]. - The company has a pipeline of six clinical-stage candidates and one preclinical candidate [8].

Group 1 - The stock price of药捷安康 (02617.HK) experienced significant volatility on September 16, with an intraday increase of over 60% followed by a decline of 53.73%, closing at 192 HKD per share and a total market capitalization of 762 billion HKD [1] - From September 11 to 15, the stock saw a cumulative increase of 361.11%, with a notable rise of 115.58% on September 15 [1] -药捷安康 is a biopharmaceutical company focused on developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, currently in the clinical registration phase [1] Group 2 - The company has not yet achieved commercialization, with projected losses of 343 million CNY and 275 million CNY for the years 2023 and 2024, respectively [2] - In the first half of the year, the company reported zero revenue and a loss of 123 million CNY [2] - On September 10, the company announced that its core product, Tinengotinib (TT-00420), received clinical approval for a Phase II trial for a specific type of breast cancer [1]

Core Viewpoint - The stock price of药捷安康 (02617.HK) has surged dramatically, reaching a market capitalization of over 240 billion HKD within three months of its IPO, despite the company not having any commercialized products and reporting a loss of 123 million HKD in the first half of the year [1][7]. Market Performance - As of September 16, the market capitalization of药捷安康 reached 249.3 billion HKD, surpassing established innovative pharmaceutical companies and approaching the market leader百济神州's valuation of 300 billion HKD [2]. - The stock price increased by nearly 600% over five trading days, with a peak price of 679.5 HKD on September 16 [1][6]. Investor Dynamics - The surge in stock price is attributed to significant inflows from southbound funds, which purchased over 300 million HKD worth of shares in two days [3]. - Key investors, including康方生物 and药石科技, have seen their investments yield over 50 times returns, with康方生物's shares valued at 517 million HKD compared to an initial investment of 10 million HKD [5][6]. Clinical Development - The stock's rise was triggered by the announcement of the clinical trial approval for its core product,替恩戈替尼, which targets multiple cancer pathways [3]. - As of June 30,替恩戈替尼 was involved in nine clinical trials globally, indicating a robust pipeline despite the company's current lack of revenue [3][7]. Financial Status - The company reported a net loss of 123 million HKD in the first half of the year, with research and development expenses of 98.43 million HKD and management expenses of 27.47 million HKD [7]. - As of June 30, the company held cash and cash equivalents of 449 million HKD, with total equity of 582 million HKD [7].

智通财经APP获悉，药捷安康-B(02617)尾盘跌幅进一步扩大，低见165港元，较日内高点已跌超75%， 总市值由日内最高约2700亿港元跌至不足700亿港元。截至发稿，跌60.12%，报165.5港元，全天成交额 43.45亿港元，振幅达123.98%。 消息面上，药捷安康今日午间发布称公告，公司交易价格及成交量近期出现异常变动。董事会确认，概 不知悉导致股份出现该等股价及成交量异常变动之任何原因；或任何须予公布以避免股份出现虚假市场 之资料；或根据上市规则须予披露之任何内幕消息。董事会亦确认，本集团之业务营运维持正常，且本 集团之业务营运及财务状况并无重大变动。本公司股东及潜在投资者于买卖本公司证券时务请审慎行 事。 ...

今年，港股市场最强妖股问世。 3个月50倍、市值一度猛超2500亿港元、营收为0、上半年亏损超1亿…… 无论哪个数据拉出来，6月才刚刚上市的药捷安康创下的"战绩"都能让人虎躯一震。 短短3个月，这只创新药"超级黑马"上演的狂飙大戏，缔造了资本市场惊天暴涨神话，也成为了今年港 股医药最强"鬼故事"。 在持续的蒙眼狂奔过后，今天药捷安康突然极限坠落，资本上演大逃杀正： 早上最高飙涨超60%，下午火速暴跌近50%，全天振幅超110%。 危险的狂欢 这场危险狂欢的背后，到底有多夸张？ 最近5个交易日，药捷安康一度累涨超800%。 继昨日暴涨逾115%后，周二药捷安康-B早盘继续疯狂，盘中一度涨63%，创上市新高。 不过午后，该股却突然直线高位跳水。 此前，药捷安康已实现4连升，市值最高逼近2700亿港元，超过了康方生物、信达生物。 一轮疯狂暴涨后，市场甚至已经大胆预期，未来它将超过百济神州、恒瑞医药，成为新一代医药龙头。 不过，今天午后高台跳水后，药捷安康市值已经挥发了近2000亿港元，目前市值不足千亿港元。 | | THE RIT HIT INC INC. HC PAC PAC INC 30 30 10 100 1 ...

然而与这场资本狂欢形成鲜明对比的是，公司同日公告明确表示："概不知悉股价异动原因，业务营运及财务状况无重大变动"。 更值得关注的是，这家尚无任何商业化产品、上半年亏损1.23亿元的企业，其背后基石投资者康方生物（09926.HK）与药石科技 （300725.SZ）等所持股份将于12月23日解禁，目前浮盈已超50倍。 药石科技告诉以投资者身份致电的财联社记者，"公司与药捷安康是财务投资者关系，公司还与药捷安康存在业务往来，有一些药物研发方 面协作。" 9月16日，港股市场创新药板块再现疯狂一幕。药捷安康（02617.HK）盘中市值超过2400亿港元。这只6月23日才登陆港交所的生物医药 新股，在短短三个月内股价较13.15港元的发行价飙升50倍，近5个交易日累计涨幅更是接近600%。 逼近创新药一哥百济神州港股市值 药捷安康的股价演绎堪称港股市场的"现象级"行情。继9月15日以115.58%的惊人涨幅收报415港元后，该股今日延续疯狂走势，截至今日 盘中涨幅收窄至49.40%，报620港元，总市值达2461亿港元。 财联社记者注意到，截至盘中，药捷安康市值达到2493亿港元，这将一众老牌创新药企远远甩在身后—— ...

（文章来源：每日经济新闻） 每经AI快讯，9月16日，药捷安康-B跌超40%，早盘一度涨超60%，全天振幅超100%，股价跌破250港 元，总市值回落至1000亿港元下方，成交额近35亿港元。 ...

9月16日下午，药捷安康-B（02617.HK）股价突然大跳水，截至发稿，股价大跌45%，每股报228港元，该股今日曾大涨 63%，最高每股报679.5港元。 值得注意的是，上周五药捷安康-B暴涨77%，周一（9月15日）药捷安康-B再次大涨115.58%。截至周一，药捷安康发行价 仅为13.15港元，上市不到3个月，药捷安康累计涨超30倍，市值突破1200亿港元。 药捷安康是一家以临床需求为导向、处于注册临床阶段的生物制药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小 分子创新疗法。药捷安康目前还没有商业化产品，今年上半年，公司的营业收入为0，亏损1.23亿元。 就在上周一（9月8日），该公司刚刚调入港股通标的名单，这也意味着南向资金可以通过港股通渠道买入该股。 9月10日，药捷安康公告，其核心产品替恩戈替尼（Tinengotinib，TT-00420）联合氟维司群治疗经治失败的激素受体阳性 （HR+）且人表皮生长因子受体2阴性或低表达（HER2-）的复发或转移性乳腺癌Ⅱ期临床试验，已于9月10日获得了中国 国家药品监督管理局的临床默示许可。 公告还称，替恩戈替尼早期临床研究结果表明，替恩戈替尼单药在经历 ...

北京商报讯（记者 丁宁）9月16日，药捷安康（02617.HK）盘中股价跳水翻绿后，盘中跌幅继续扩大， 一度跌逾50%，截至北京商报记者发稿，药捷安康报226港元/股，跌幅为45.54%。 ...

每经编辑｜何小桃 9月16日下午，药捷安康-B（02617.HK）股价突然大跳水，截至发稿，股价大跌45%，每股报228港元，该股今日曾大涨63%，最高每股报679.5港元。 值得注意的是，上周五药捷安康-B暴涨77%，周一（9月15日）药捷安康-B再次大涨115.58%。截至周一，药捷安康发行价仅为13.15港元，上市不到3个 月，药捷安康累计涨超30倍，市值突破1200亿港元。 药捷安康是一家以临床需求为导向、处于注册临床阶段的生物制药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。药捷安康目前还 没有商业化产品，今年上半年，公司的营业收入为0，亏损1.23亿元。 就在上周一（9月8日），该公司刚刚调入港股通标的名单，这也意味着南向资金可以通过港股通渠道买入该股。 9月10日，药捷安康公告，其核心产品替恩戈替尼（Tinengotinib，TT-00420）联合氟维司群治疗经治失败的激素受体阳性（HR+）且人表皮生长因子受体 2阴性或低表达（HER2-）的复发或转移性乳腺癌Ⅱ期临床试验，已于9月10日获得了中国国家药品监督管理局的临床默示许可。 公告还称，替恩戈替尼早期临床研究结果表明，替恩戈 ...